Stay Informed

Sign up for news & alerts

Already signed up?
Login here
What Can I Do?


Get Help
Need alcohol or drug help for yourself or someone else? GET HELP
Continuing Education
Free online courses for addiction counselors LEARN ONLINE
Resources
Resources
Find useful publications, online documents & more.


DrugScreening.org


 

Gene May Determine Smoking-Cessation Success
April 24, 2001

Share Share Email
Email
Print
Print
SubscribeSubscribe
Research Summary

A new study found that a gene linked to alcohol and other drug addiction may also determine whether a person can successfully quit smoking, CNN reported April 23.

Researchers at the M.D. Anderson Cancer Center in Houston, Texas, studied 134 people who participated in a smoking-cessation program. All of the participants had a particular gene called DRD2, which is a dopamine receptor.

Dopamine is a neurotransmitter that influences how brain cells communicate with each other. The DRD2 gene, which has been found in people with obesity, alcoholism, cocaine addiction, and pathological gambling, is made up of A1 or A2 alleles.

For the study, all participants were given a nicotine patch and received counseling. Some of the smokers also received an antidepressant drug or a placebo.

The researchers found that 37 percent of those taking the antidepressant abstained from cigarettes for 18 weeks, compared with 25 percent of the placebo group.

But researchers also found that smokers with an A1 DRD2 gene were more likely to start smoking again after the 18 weeks.

"If you have the A1 allele, you quit smoking less often," said Paul Cinciripini, director of the Tobacco Research and Treatment Center at M.D. Anderson, and one of the study's authors.

Cinciripini pointed out that the study's findings could provide added assistance to smokers trying to quit. He explained that smokers could be screened for the gene and receive certain drugs that may help them to successfully stop smoking.

Dr. Dileep Bal, president of the American Cancer Society, added, "If we genetically characterize the dependent smoker, we can potentially tailor-make drugs for each genetic profile or to simplify, if you have genetic profile x, y and z, you can find different drugs that work for x, y and z."

The study, the first to examine how genes can contribute to or hinder smoking-cessation efforts, was presented at an American Cancer Society conference in Dana Point, Calif.

COMMENTS ON THIS ARTICLE:

Your Turn! Post a public comment (read guidelines):

Name:

Comment:
(limit 200
words)

Enter this word
(help):
Change

GUIDELINES: 
To keep this feature useful for all, please:

  1. Keep it clean, courteous, and on-topic. Comments are meant for thoughtful discussion of the article published above.

  2. Do not post promotional links to organizations, products or services, or personal requests for assistance (get help).

  3. Proof your comments carefully, use good spelling and punctuation, and don't use ALL CAPS. Comments are published immediately and cannot be edited.

Deceptive, slanderous and commercially-motivated posts are prohibited. We reserve the right to remove comments not conforming to these guidelines. (Report a comment).

Have questions or feedback? Contact us.